Kezar Life Sciences (NASDAQ:KZR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kezar Life Sciences (NASDAQ:KZR) to a hold rating in a research report report published on Saturday morning.

KZR has been the topic of a number of other reports. William Blair reissued a “market perform” rating on shares of Kezar Life Sciences in a report on Friday, October 17th. Jefferies Financial Group downgraded shares of Kezar Life Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $18.00 to $7.00 in a research report on Friday, October 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Kezar Life Sciences in a report on Wednesday, October 8th. TD Cowen lowered Kezar Life Sciences from a “strong-buy” rating to a “strong sell” rating in a report on Friday, October 17th. Finally, Wells Fargo & Company set a $5.00 price target on Kezar Life Sciences and gave the stock an “equal weight” rating in a research report on Friday, October 17th. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $6.00.

Kezar Life Sciences Stock Performance

Shares of KZR stock opened at $6.21 on Friday. The stock has a market capitalization of $45.46 million, a price-to-earnings ratio of -0.74 and a beta of 0.70. Kezar Life Sciences has a one year low of $3.53 and a one year high of $7.61. The company’s 50-day simple moving average is $5.15 and its 200-day simple moving average is $4.54. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.06 and a current ratio of 7.07.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($1.53) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.28. Equities analysts anticipate that Kezar Life Sciences will post -4.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kezar Life Sciences

Hedge funds have recently made changes to their positions in the business. Peapod Lane Capital LLC boosted its position in shares of Kezar Life Sciences by 9.3% during the third quarter. Peapod Lane Capital LLC now owns 125,773 shares of the company’s stock worth $491,000 after buying an additional 10,650 shares during the period. Landscape Capital Management L.L.C. bought a new stake in Kezar Life Sciences during the 3rd quarter valued at $51,000. Woodline Partners LP acquired a new position in Kezar Life Sciences during the 1st quarter worth $125,000. Stonepine Capital Management LLC boosted its position in Kezar Life Sciences by 69.9% during the 2nd quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock worth $778,000 after acquiring an additional 69,859 shares during the period. Finally, BML Capital Management LLC grew its stake in shares of Kezar Life Sciences by 13.5% in the third quarter. BML Capital Management LLC now owns 720,787 shares of the company’s stock worth $2,811,000 after purchasing an additional 85,604 shares in the last quarter. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.